Microbiome startup Solarea Bio raises $11.2 million Series A for "food as medicine" applications

October 26, 2020
Emerging Ecosystems in Agrifood and Health More...
Average importance

This funding round was led by S2G Ventures and Bold Capital Partners. By leveraging bioinformatics, Solarea develops synergistic combinations of bacteria, fungi, and prebiotic fibers with anti-inflammatory capabilities by studying microbial populations colonizing healthy foods. The company will use this funding to further the development of its functional cocktail for the dietary management of the metabolic processes that cause musculoskeletal conditions. Solarea's research shows that microbiome research is fast expanding beyond just gut health conditions. As outlined in our report, companies seeking to thrive in the future should look to act on opportunities within the realm of "food as medicine," which will become increasingly important.

For the original news article, click here .

Further Reading

Skin Microbiome

Technology | June 08, 2020

Modulation of microorganisms that reside on the skin. Not part of subscription

DSM invests in plant-derived functional ingredients company Phynova

News Commentary | May 15, 2020

Building on a distribution agreement with Phynova in 2019, DSM led the €10 million investment in the Oxford‑based company, which makes functional ingredients derived from plants. Phynova will use this funding to scale its mulberry leaf‑derived ingredient "Reducose," which regulates blood glucose ... To read more, click here.

Evolve BioSystems raises $55 million to expand its probiotics for infant health application

News Commentary | February 12, 2021

This Series D funding round was led by Cargill and Manna Tree and will help Evolve expand the market reach of its probiotic supplement targeting infant health. This investment also signals Cargill's sustained interest in the microbiome space, coming on the heels of its previous investment in ... Not part of subscription